Protara Therapeutics, Inc.
TARA
$3.11
$0.010.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.08% | 21.28% | 3.28% | -4.95% | -12.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.58% | 19.18% | 29.63% | 15.23% | -12.18% |
| Operating Income | -55.58% | -19.18% | -29.63% | -15.23% | 12.18% |
| Income Before Tax | -57.26% | -7.38% | -24.93% | -13.78% | 15.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.26% | -7.38% | -24.93% | -13.78% | 15.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.26% | -7.38% | -24.93% | -13.78% | 15.77% |
| EBIT | -55.58% | -19.18% | -29.63% | -15.23% | 12.18% |
| EBITDA | -55.87% | -19.32% | -30.14% | -15.30% | 12.30% |
| EPS Basic | 21.00% | 69.87% | 46.28% | 42.18% | 55.15% |
| Normalized Basic EPS | 21.00% | 69.88% | 46.29% | 42.18% | 55.14% |
| EPS Diluted | 21.00% | 69.87% | 46.28% | 42.18% | 55.15% |
| Normalized Diluted EPS | 21.00% | 69.88% | 46.29% | 42.18% | 55.14% |
| Average Basic Shares Outstanding | 99.08% | 256.43% | 132.58% | 96.77% | 87.77% |
| Average Diluted Shares Outstanding | 99.08% | 256.43% | 132.58% | 96.77% | 87.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |